ABT-888 (veliparib)With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian TubeCancer, Triple-NegativeBreast Cancer, and Low-Grade Non-Hodgkin's Lymphoma
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Triple-negative breast cancer which has progressed following at least one line of therapy. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral CT scan.
Type of study:
Randomized, Phase II trial for patients with triple-negative breast cancer
Patients will be randomized to receive either oral cyclophosphamide alone or oral cyclophosphamide in combination with ABT-888.
For all study sites, please contact:
Deborah E. Allen, R.N. (301) 402-5640 email@example.com
University of California, Davis
Davis, California, 95616
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 33612
University of Chicago
Chicago, Illinois, 60637
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Mayo Clinic, Rochester
Rochester, Minnesota, 55905
University of Nebraska Med. Ctr. Eppley Cancer Ctr.
Omaha, Nebraska, 68198-5950
Montefiore Medical Center
Bronx, New York, 10467
Memorial Sloan Kettering Cancer Center
New York, New York, 10021
Ohio State University
Columbus, Ohio, United States, 43210-1240
MD Anderson Cancer Center
Houston, Texas, 77030-4096
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.